Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "Esai"

35 News Found

No link between the use of ranitidine and cancer risk, claims Nature
News | February 24, 2023

No link between the use of ranitidine and cancer risk, claims Nature

N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.


TTK Healthcare receives a balance amount of Rs. 208.39 Cr from BSV Pharma
News | December 07, 2022

TTK Healthcare receives a balance amount of Rs. 208.39 Cr from BSV Pharma

TTK Healthcare Limited received from BSV Pharma Pvt. Ltd. a sum of Rs. 593.11 crore on 9th May, 2022


Aether Industries Q4 FY22 revenue up 26.8%; Profit up 13.8%
News | June 18, 2022

Aether Industries Q4 FY22 revenue up 26.8%; Profit up 13.8%

Revenues from operations for the full year ended March 31, 2022 stood at Rs. 590.05 crore as compared to Rs. 449.82 crore in FY21


Aadi Bioscience announces collaborations with next generation sequencing leaders
Biotech | May 09, 2022

Aadi Bioscience announces collaborations with next generation sequencing leaders

The company enters into collaborations with leading next-generation sequencing (NGS) companies to facilitate trial enrollment for PRECISION 1, the Company’s Phase 2 registrational trial


Camzyos is the first and only USFDA-approved cardiac myosin inhibitor
Biotech | April 29, 2022

Camzyos is the first and only USFDA-approved cardiac myosin inhibitor

Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo


First patients ‘filter free’ after laser-assisted Inferior Vena Cava (IVC) filter removal
Public Health | April 22, 2022

First patients ‘filter free’ after laser-assisted Inferior Vena Cava (IVC) filter removal

The first use of Philips' breakthrough CavaClear solution to help patients with embedded IVC filters, including an athlete suffering from a 16-year old penetrating filter


Aadi Bioscience launches Fyarro in the USA
Biotech | February 24, 2022

Aadi Bioscience launches Fyarro in the USA

Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa


Union Budget 2022-23 : Medtech expects incentives, GST exemptions and custom duty rationalisation
Medical Device | January 30, 2022

Union Budget 2022-23 : Medtech expects incentives, GST exemptions and custom duty rationalisation

Medtech plays a vital role in the healthcare system and players in this field believe that the budget should address some of their concerns if India has to become a formidable player


Clarivate identifies seven potential blockbuster drugs in Annual Drugs to Watch report
News | January 10, 2022

Clarivate identifies seven potential blockbuster drugs in Annual Drugs to Watch report

Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma


Piramal Pharma takes a minority stake in Yapan Bio
Biotech | December 22, 2021

Piramal Pharma takes a minority stake in Yapan Bio

The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space